MarketInOut Stock Screener Log In | Sign Up
 

Design Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Design Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization640.84 mln
Float34.58 mln
Earnings Date11/11/2026

Piotroski F-Score

1 / 9
Very weak

1-Year Forecast

21.71
Transformational upside

Relative Strength

21 / 100
Significantly lagging

Debt / Equity

0.01
Debt-free

ROE

-33.87
Deeply negative

ROA

-31.98
Deeply negative

Business Description

Design Therapeutics is a clinical-stage company based in Carlsbad, California, focused on developing small molecule drugs to treat serious genetic diseases caused by abnormal DNA repeat sequences. Using its proprietary GeneTAC platform, the company is advancing treatments for conditions such as Friedreich Ataxia, Myotonic Dystrophy Type 1, Fuchs Endothelial Corneal Dystrophy, and Huntington's Disease ? all of which cause significant damage to the nervous system, muscles, heart, and other vital organs. Founded in 2017, the company aims to address diseases that currently have few or no effective treatment options.

Key Fundamentals

EPS-1.18
ROE-33.87
ROIC-1,140
ROA-31.98
EBITDA, mln-70.18
EV / EBITDA-8.37
EV / EBIT-8.29

Quote Details

Last 10.24
Change -0.25 (-2.38%)
Open 10.42
Volume 210,364
Turnover 2,154,127
Average Volume 519,194

Financial Ratios

Leverage Ratio1.07
Current Ratio18.86
Price / Book3.92
Price / Tangible Book3.92
Debt / Equity0.01

Financial Strength

Piotroski F-Score 1 / 9
1-Year Target Price21.71
Short Ratio8.67
Short % of Float14.00

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -0.68% 39 / 100   
1 Month -16.34% 21 / 100   
2 Months -13.73% 27 / 100   
6 Months -18.28% 27 / 100   
1 Year 85.17% 96 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog